Evotec (NASDAQ:EVO) Shares Gap Up to $5.15

Evotec SE (NASDAQ:EVO) shares gapped up prior to trading on Friday . The stock had previously closed at $5.15, but opened at $5.37. Evotec shares last traded at $5.36, with a volume of 13,015 shares trading hands.

Wall Street Analyst Weigh In

EVO has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded Evotec from a “hold” rating to a “buy” rating in a research note on Friday, April 12th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Evotec in a research note on Thursday, May 23rd.

Evotec Price Performance

The stock’s 50-day moving average price is $4.91 and its 200-day moving average price is $7.04. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.79 and a current ratio of 1.86.

Institutional Trading of Evotec

Several large investors have recently bought and sold shares of EVO. Mubadala Investment Co PJSC purchased a new stake in shares of Evotec in the 4th quarter worth about $53,931,000. Optiver Holding B.V. grew its position in shares of Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after purchasing an additional 69,936 shares during the last quarter. Cetera Advisors LLC purchased a new position in shares of Evotec during the 1st quarter worth approximately $188,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Evotec during the 4th quarter worth approximately $25,000. Institutional investors and hedge funds own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.